Concert Pharma (CNCE) Misses Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
March 3, 2022 6:00 AM ESTTwo Phase 3 Registrational Clinical Trials Fully Enrolled for CTP-543 for the Treatment of Alopecia Areata
CTP-543 THRIVE-AA1 Phase 3 Trial Topline Data Expected Second Quarter of 2022
CTP-543 THRIVE-AA2 Phase 3 Trial Topline Data Expected Third Quarter of 2022
Conference Call Scheduled Today at 8:30 a.m. ET
LEXINGTON, Mass.--(BUSINESS... More
